Robots that learn on the job: AgiBot tests reinforcement learning in real-world manufacturing.
Updated
January 8, 2026 6:34 PM
A humanoid robot works on a factory line, showcasing advanced automation in real-world production. PHOTO: AGIBOT
Shanghai-based robotics firm AgiBot has taken a major step toward bringing artificial intelligence into real manufacturing. The company announced that its Real-World Reinforcement Learning (RW-RL) system has been successfully deployed on a pilot production line run in partnership with Longcheer Technology. It marks one of the first real applications of reinforcement learning in industrial robotics.
The project represents a key shift in factory automation. For years, precision manufacturing has relied on rigid setups: robots that need custom fixtures, intricate programming and long calibration cycles. Even newer systems combining vision and force control often struggle with slow deployment and complex maintenance. AgiBot’s system aims to change that by letting robots learn and adapt on the job, reducing the need for extensive tuning or manual reconfiguration.
The RW-RL setup allows a robot to pick up new tasks within minutes rather than weeks. Once trained, the system can automatically adjust to variations, such as changes in part placement or size tolerance, maintaining steady performance throughout long operations. When production lines switch models or products, only minor hardware tweaks are needed. This flexibility could significantly cut downtime and setup costs in industries where rapid product turnover is common.
The system’s main strengths lie in faster deployment, high adaptability and easier reconfiguration. In practice, robots can be retrained quickly for new tasks without needing new fixtures or tools — a long-standing obstacle in consumer electronics production. The platform also works reliably across different factory layouts, showing potential for broader use in complex or varied manufacturing environments.
Beyond its technical claims, the milestone demonstrates a deeper convergence between algorithmic intelligence and mechanical motion.Instead of being tested only in the lab, AgiBot’s system was tried in real factory settings, showing it can perform reliably outside research conditions.
This progress builds on years of reinforcement learning research, which has gradually pushed AI toward greater stability and real-world usability. AgiBot’s Chief Scientist Dr. Jianlan Luo and his team have been at the forefront of that effort, refining algorithms capable of reliable performance on physical machines. Their work now underpins a production-ready platform that blends adaptive learning with precision motion control — turning what was once a research goal into a working industrial solution.
Looking forward, the two companies plan to extend the approach to other manufacturing areas, including consumer electronics and automotive components. They also aim to develop modular robot systems that can integrate smoothly with existing production setups.
Keep Reading
METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body
Updated
May 14, 2026 3:02 PM
HIV-1 virus particles, coloured red. PHOTO: UNSPLASH
Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.
The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.
Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.
The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.
That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.
METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.
The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.
One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.
Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.
METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.
The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.
Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."
The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.
For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.